Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II clinical study of AP1189 in adults diagnosed with COVID-19 and with early signs of Acute Respiratory Distress Syndrome (ARDS)

Next Previous
Search
Trial Profile

Phase II clinical study of AP1189 in adults diagnosed with COVID-19 and with early signs of Acute Respiratory Distress Syndrome (ARDS)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Resomelagon (Primary)
  • Indications SARS-CoV-2 acute respiratory disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms RESOVIR-1

    • Most Recent Events

    • 12 Oct 2022 New trial record
    • 23 Sep 2022 According to a SynAct Pharma media release, Prof. Mauro Teixeira is the primary investigator for this trial.
    • 23 Sep 2022 According to a SynAct Pharma media release, trial design has been approved by authorities in Brazil, is based upon strong scientific evidence supporting the role of AP1189 in modulating inflammatory responses. First part will initiate as soon as medicine for the study has arrived at the clinical site.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top